James Luedeke, MD
Family Medicine · Minster, OHNPI 1083602254
Payments from drug & device makers
Across 165 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$593
- Pfizer$329
- Novo Nordisk$320
- Lilly USA, LLC$177
- AstraZeneca$149
- Abbott$127
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,739100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $593 |
| Pfizer | 22 | $329 |
| Novo Nordisk | 21 | $320 |
| Lilly USA, LLC | 11 | $177 |
| AstraZeneca | 10 | $149 |
| Abbott | 7 | $127 |
| Organogenesis Inc. | 4 | $117 |
| Exact Sciences | 5 | $110 |
| E.r. Squibb & Sons, L.L.C. | 6 | $103 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $96 |
| Myriad Women's Health, Inc. | 2 | $95 |
| GSK | 5 | $90 |
| Boehringer Ingelheim | 5 | $80 |
| Mimedx Group, Inc. | 1 | $74 |
| Boston Scientific | 1 | $57 |
| Amgen | 4 | $54 |
| Genentech USA, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Shield Therapeutics Inc | 1 | $20 |
| Smith+Nephew | 1 | $20 |
| Next Science LLC | 1 | $18 |
| Cranial Technologies, Inc | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$2,739 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $68,723 |
| JanuviaSitagliptin Phosphate | 53 | $65,160 |
| OzempicSemaglutide | 50 | $52,995 |
| JardianceEmpagliflozin | 55 | $45,436 |
| XareltoRivaroxaban | 33 | $28,574 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $27,717 |
| TrulicityDulaglutide | 16 | $24,238 |
| FarxigaDapagliflozin Propanediol | 12 | $19,929 |
| MyrbetriqMirabegron | 11 | $9,681 |
| EntrestoSacubitril/Valsartan | 11 | $9,301 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $8,992 |
| Bydureon BciseExenatide Microspheres | 13 | $8,962 |
| Spiriva HandihalerTiotropium Bromide | 16 | $8,816 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,603 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $329 | $68,72368 claims |
| MerckJanuvia | $12 | $65,16053 claims |
| Novo NordiskOzempic | $320 | $52,99550 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $80 | $50,83266 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $90 | $33,32144 claims |
| Lilly USA, LLCTrulicity | $177 | $24,23816 claims |
| AstraZenecaFarxiga | $149 | $19,92912 claims |
| AbbVieSynthroid | $593 | $1,14943 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Minster
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.